When Shelves Run Empty: How Indian Contract Manufacturers Have Become America's Backstop Against Drug Shortages

Somewhere in a sterile filling suite outside Hyderabad, a batch of injectable methotrexate is being prepared under conditions that mirror—and in some audited metrics, exceed—those found in New Jersey or North Carolina. The destination? A network of American oncology clinics that, months earlier, had been rationing doses because their primary domestic supplier had suspended operations following an FDA warning letter. The Indian contract manufacturing organization, or CMO, received an expedited purchase order. It delivered.

This scenario is no longer exceptional. It has become, for an increasing number of American hospital pharmacies and group purchasing organizations, a carefully managed expectation.

The Anatomy of a Drug Shortage

The FDA defines a drug shortage as a period during which the total supply of all clinically interchangeable versions of an FDA-regulated drug is inadequate to meet current or projected demand. By that definition, the United States recorded more than 300 active drug shortages in 2023 alone—a figure that, while not unprecedented, reflects a structural fragility in domestic pharmaceutical manufacturing that has persisted for over two decades.

The causes are well-documented: aging manufacturing infrastructure, thin profit margins on generic sterile injectables, quality-related facility shutdowns, and a supply chain for active pharmaceutical ingredients that was never designed to absorb simultaneous global disruptions. What is less frequently examined is who steps in when the system buckles.

Increasingly, the answer is India.

Contract Manufacturing's Quiet Ascent

India's contract manufacturing sector has grown substantially over the past decade, driven in part by deliberate investment in US-compliant quality systems. The country is now home to more FDA-inspected pharmaceutical manufacturing facilities outside the United States than any other nation—a distinction that carries real operational weight when American buyers need to qualify a new supplier quickly.

For CMOs specifically, the value proposition extends beyond cost. A well-established Indian contract manufacturer brings pre-validated processes, experienced regulatory affairs teams, and—critically—existing Drug Master Files registered with the FDA. When a domestic shortage triggers an accelerated supplier qualification process, these pre-existing filings can compress timelines from years to months.

Dr. Ravi Shankar Pillai, a regulatory consultant who has advised multiple Indian CMOs on US market entry, describes the dynamic bluntly: "American buyers used to treat Indian CMOs as a cost optimization strategy. After the pandemic, they started treating them as a risk mitigation strategy. That is a fundamental shift in how procurement decisions are made."

Case Studies in Crisis Response

The shortage of sterile injectable amikacin—a last-resort antibiotic used in hospital settings—in 2022 illustrates how this system functions under pressure. When a major US manufacturer encountered contamination-related production halts, several hospital networks activated contingency sourcing protocols that had been developed, but never fully tested, during the COVID-19 era. Two Indian CMOs with pre-existing FDA registrations and current Good Manufacturing Practice compliance were contacted within seventy-two hours. Both had available capacity. One had finished goods inventory that could be released for export following a documentation review. Shipments arrived at US distribution centers within three weeks of initial contact.

A similar pattern emerged during the 2023 shortage of cisplatin and carboplatin, chemotherapy agents that became critically scarce when a major domestic producer voluntarily recalled its products. Indian manufacturers with existing abbreviated new drug applications on file were able to accelerate production schedules, and the FDA used its shortage-related regulatory flexibility to facilitate faster review of supplemental submissions. While the shortage was not fully resolved, oncologists at several major cancer centers credited the Indian manufacturing sector with preventing what could have been a far more severe treatment disruption.

Regulatory Hurdles and How They Are Cleared

It would be misleading to suggest that Indian CMOs can simply substitute for domestic manufacturers at will. The regulatory architecture governing pharmaceutical manufacturing in the United States is exacting, and for good reason. Every manufacturing site must be registered with the FDA. Every drug product must be covered by an approved application. Every change to a manufacturing process or site must, in most cases, be reported or approved before commercial distribution.

What has changed is the FDA's willingness to use the tools at its disposal during shortage emergencies. Under its shortage-related enforcement policies, the agency can exercise discretion in how it handles certain regulatory submissions, prioritize inspections of facilities that could alleviate a shortage, and grant temporary importation permissions for drugs manufactured at sites not yet fully approved for the US market.

Indian CMOs that have invested in robust quality management systems, maintained transparent communication with FDA inspectors, and built relationships with US-based regulatory consultants are positioned to move quickly when these tools are deployed. Those that have not are effectively invisible to American buyers in a crisis.

"The CMOs that are winning US shortage business are the ones that spent the last five years building trust before they needed to use it," notes one senior director of pharmacy at a large Midwestern health system who requested anonymity to speak candidly about sourcing decisions. "We don't have time during a shortage to audit a facility we've never heard of."

Hospital Systems Rethink Their Supplier Maps

The institutional response to recurring shortages has been a quiet but significant restructuring of how American hospital systems think about their pharmaceutical supply chains. Group purchasing organizations—the entities that negotiate drug contracts on behalf of hospitals—have begun formalizing relationships with Indian CMOs in ways that would have been considered unconventional five years ago.

Some health systems are now requiring that their primary suppliers maintain geographic diversification in their own manufacturing networks, effectively mandating an Indian or European backup facility as a condition of contract renewal. Others are establishing direct relationships with Indian CMOs as secondary suppliers, maintaining small but continuous purchase volumes to keep those channels active and audited.

The financial logic is straightforward. The cost of managing a drug shortage—including clinical staff time, alternative therapy costs, patient safety risks, and regulatory reporting obligations—routinely exceeds the cost of maintaining a diversified supplier relationship by a substantial margin.

The Road Ahead

The role of Indian contract manufacturers in the American drug supply chain is unlikely to diminish. If anything, the structural pressures driving US shortages—continued consolidation among domestic generic manufacturers, persistent underinvestment in sterile injectable capacity, and growing demand for complex formulations—suggest that the need for reliable external manufacturing partners will intensify.

What this means for patients is a pharmaceutical supply chain that is more geographically dispersed and, paradoxically, more resilient than it might appear from the outside. The label on a hospital IV bag may carry an American brand name. The drug inside may have been manufactured in Telangana or Gujarat, by a team that spent years preparing for exactly this moment.

For US healthcare administrators and policymakers, the imperative is clear: understanding this invisible infrastructure is no longer optional. It is a prerequisite for managing the next shortage before it becomes a crisis.